Case Studies in Cardiovascular Risk Reduction with Non-statin Therapies: Rapid Fire Roundtable

In this rapid-fire roundtable session, Clinical Lipid Specialists Joyce Ross, MSN, CRNP and Dr. Lynne Braun PhD, CNP discuss PCSK9 Inhibitors in practice, including the latest data from CV outcomes studies. They demonstrate how these trials will impact practice through dynamic case studies, including a patient’s with diabetic dyslipidemia, ASCVD and familial hypercholesterolemia.

Lipid Management
Member Cost: $0Non-member Cost: $0
Credits: 1.0 CE contact hours, 0.7 CE pharmacology hours

Course Overview

In this rapid-fire roundtable session, Clinical Lipid Specialists Joyce Ross, MSN, CRNP and Dr. Lynne Braun PhD, CNP discuss PCSK9 Inhibitors in practice, including the latest data from CV
outcomes studies. They demonstrate how these trials will impact practice through dynamic case studies, including a patient’s with diabetic dyslipidemia, ASCVD, and familial hypercholesterolemia.

Register

Learning Objectives

Upon completion of this continuing education course, participants will be able to:

  • Review the latest clinical evidence regarding the impact of PCSK9 inhibitors and very low LDL-C on CV outcomes.
  • Utilize PCSK9 inhibitors in patients who may benefit in accordance with the latest clinical evidence and recommendations.

Faculty

  • Joyce Ross, MSN, CRNP, FNLA
  • Lynne Braun PhD, CNP